美国OncoMed  
OncoMed制药是一个临床阶段的公司发现并开发新型疗法，针对癌症干细胞，细胞认为是能够驱动肿瘤生长，复发和转移。癌症干细胞研究的领导者，该公司已建立了癌症干细胞的蛋白质抗体库的实体肿瘤，如胰腺癌，乳腺癌，肠癌和肺癌的治疗。 OncoMed已推进到诊所指，OMP-21M18-59R5，OMP的，和OMP-18R5，该目标的关键癌症干细胞的信号包括Notch和Wnt信号通路的三防癌干细胞的单克隆抗体。此外，OncoMed的管道包括了一些新的临床前候选产品，针对多个验证癌症干细胞的途径。 OncoMed与拜耳医药保健制药和葛兰素史克公司已形成战略联盟。私人持有，OncoMed的投资者包括：The Vertical Group, Morgenthaler Ventures, Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay Partners and GlaxoSmithKline.


OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastasis. A leader in cancer stem cell research, the company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers. OncoMed has advanced three anti- cancer stem cell monoclonal antibodies into the clinic, OMP-21M18, OMP-59R5, and OMP-18R5, which target key cancer stem cell signaling pathways including Notch and Wnt. In addition, OncoMed's pipeline includes several novel preclinical product candidates targeting multiple validated cancer stem cell pathways. OncoMed has formed strategic alliances with Bayer HealthCare Pharmaceuticals and GlaxoSmithKline. Privately-held, OncoMed's investors include: US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay Partners and GlaxoSmithKline.